References
- Bosanquet A G, McCann S R, Crotty G M, Mills M J, Catovsky D. Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay. Acta Haematol 1995; 93: 73–79
- Thornton P D, Hamblin M, Treleaven J G, Matutes E, Lakhani A K, Catovsky D. High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Leuk Lymphoma 1999; 34: 167–170
- Thornton P D, Matutes E, Bosanquet A G, Lakhani A K, Grech H, Ropner J E, et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003; 82: 759–765
- Castro J E, Sandoval-Sus J D, Bole J, Rassenti L, Kipps T J. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia, in press
- Castro J E, Bole J E, Prada C E, Loria O, Kipps T J. Rituximab and high-dose methylprednisolone as a first-line treatment for patients with chronic lymphocytic leukemia. Blood 2005; 106: 2969, (abstract)
- Bowen D A, Call T G, Jenkins G D, Zent C S, Schwager S M, Van Dyke D L, et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavourable cytogenetic features. Leuk Lymphoma 2007; 48: 2412–2417
- Dungarwalla M, Evans S O, Riley U, Catovsky D, Dearden C E, Matutes E. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 2008; 93: 475–476
- Quinn J, Sajir M, Chipperfield K, Treacy M, D'Sa S, Nathwani A. Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukaemia. Leuk Lymphoma 2008; 49: 1995–1998
- Pettitt A R, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006; 20: 1441–1415